Literature DB >> 10859378

The strong positive correlation between effective affinity and infectivity neutralization of highly cross-reactive monoclonal antibody IIB4, which recognizes antigenic site B on influenza A virus haemagglutinin.

F Kostolanský1, E Varecková, T Betáková, V Mucha, G Russ, S A Wharton.   

Abstract

Monoclonal antibody (MAb) IIB4 displays a rare combination of virus neutralization (VN) activity and broad cross-reactivity with influenza A virus strains of the H3 subtype isolated in a period from 1973 to 1988. The epitope of this antibody has been identified as around HA1 residues 198, 199 and 201. Here we report that residues 155, 159, 188, 189 and 193 also influence the binding of this antibody. We have used this antibody to study the relationship between antibody affinity and VN activity. Using one MAb and a single epitope on the haemagglutinin (HA) of different influenza viruses we found a strong positive correlation between effective affinity and VN activity of MAb IIB4. A 10-fold increase in effective affinity corresponded to the 2000-fold increase in VN titre. It follows from the law of mass action that for an effective affinity K=9x10(8) l/mol, 50% VN was achieved at approx. 10% occupation of HA spikes with antibody. In contrast, for an effective affinity K=6x10(7) l/mol, to achieve 50% VN, occupation of up to 98% of HA spikes was required. An effective affinity about K=6x10(7) l/mol thus represents the limiting value for VN because a further decrease in the affinity cannot be compensated by a higher concentration of antibody.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10859378     DOI: 10.1099/0022-1317-81-7-1727

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  10 in total

1.  Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype.

Authors:  Jing Qi Feng; Krystyna Mozdzanowska; Walter Gerhard
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

2.  Epitope analysis for influenza vaccine design.

Authors:  Enrique T Muñoz; Michael W Deem
Journal:  Vaccine       Date:  2005-01-19       Impact factor: 3.641

3.  Accumulation of amino acid substitutions promotes irreversible structural changes in the hemagglutinin of human influenza AH3 virus during evolution.

Authors:  Katsuhisa Nakajima; Eri Nobusawa; Alexander Nagy; Setsuko Nakajima
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

Review 4.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

5.  Initiating a watch list for Ebola virus antibody escape mutations.

Authors:  Craig R Miller; Erin L Johnson; Aran Z Burke; Kyle P Martin; Tanya A Miura; Holly A Wichman; Celeste J Brown; F Marty Ytreberg
Journal:  PeerJ       Date:  2016-02-16       Impact factor: 2.984

Review 6.  Antibody Cross-Reactivity in Antivenom Research.

Authors:  Line Ledsgaard; Timothy P Jenkins; Kristian Davidsen; Kamille Elvstrøm Krause; Andrea Martos-Esteban; Mikael Engmark; Mikael Rørdam Andersen; Ole Lund; Andreas Hougaard Laustsen
Journal:  Toxins (Basel)       Date:  2018-09-27       Impact factor: 4.546

7.  Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity.

Authors:  Kwadwo A Kusi; Bart W Faber; Alan W Thomas; Edmond J Remarque
Journal:  PLoS One       Date:  2009-12-01       Impact factor: 3.240

8.  The Analysis of B-Cell Epitopes of Influenza Virus Hemagglutinin.

Authors:  D N Shcherbinin; S V Alekseeva; M M Shmarov; Yu A Smirnov; B S Naroditskiy; A L Gintsburg
Journal:  Acta Naturae       Date:  2016 Jan-Mar       Impact factor: 1.845

9.  Broad neutralizing human monoclonal antibodies against influenza virus from vaccinated healthy donors.

Authors:  Ritsuko Kubota-Koketsu; Hiroyuki Mizuta; Masatoshi Oshita; Shoji Ideno; Mikihiro Yunoki; Motoki Kuhara; Naomasa Yamamoto; Yoshinobu Okuno; Kazuyoshi Ikuta
Journal:  Biochem Biophys Res Commun       Date:  2009-07-04       Impact factor: 3.575

10.  Cross-Reactivity, Epitope Mapping, and Potency of Monoclonal Antibodies to Class 5 Fimbrial Tip Adhesins of Enterotoxigenic Escherichia coli.

Authors:  Yang Liu; Sakina Shahabudin; Sami Farid; Lanfong H Lee; Annette L McVeigh; Milton Maciel; Steven T Poole; Matthew Broadman; Michael G Prouty; Stephen J Savarino
Journal:  Infect Immun       Date:  2020-10-19       Impact factor: 3.441

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.